Login or Register
Biomedical Learning Institute Taught by the Experts
Thought Leaders		 Biomedical Learning Institute
Please Note: The Oncology Learning Center has changed its name to Biomedical Learning Institute
Overview | Agenda | Hotel Accommodations | Registration

Symposium Chair

Steven T. Rosen, MD, FACP
Steven T. Rosen, MD, FACP
Director, Robert H. Lurie Cancer Center
Northwestern University
Chicago, IL

Expert Faculty

Michael Deininger, MD, PhD
Michael Deininger, MD, PhD
Chief, Division of Hematology and Hematologic Malignancies
M.M. Wintrobe Professor of Medicine
University of Utah
Huntsman Cancer Institute
Salt Lake City, UT

Leo I. Gordon, MD
Leo I. Gordon, MD
Professor, Division of Hematology / Oncology
Division of Hematology/Oncology
Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, IL

Andre Goy, MD, MS
André Goy, MD, MS
Chief, Lymphoma Division
The Cancer Center
Hackensack University Medical Center
Hackensack, NJ

Virginia M. Klimek, MD
Virginia M. Klimek, MD
Associate Professor of Medicine
Leukemia Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY

Tibor Kovacsovics, MD
Tibor Kovacsovics, MD
Associate Professor of Medicine
Director, Acute Leukemia Program
Center for Hematologic Malignancies
Oregon Health & Science University
Portland, OR

John P. Leonard, MD
John P. Leonard, MD
Professor of Medicine
Weill Cornell Medical College
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medical College
New York, NY

Shuo Ma, MD, PhD
Shuo Ma, MD, PhD
Assistant Professor of Medicine
Division of Hematology/Oncology
Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, IL

Nikhil C. Munshi, MD
Nikhil C. Munshi, MD
Associate Professor of Medicine
Harvard Medical School
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA

Owen A. OConnor, MD
Owen A. O'Connor, MD
Chief, Division of Hematology and Medical Oncology
Deputy Cancer Center Director
NYU Cancer Institute
NYU Langone Medical Center
New York, NY

S. Vincent Rajkumar, MD
S. Vincent Rajkumar, MD
Professor of Medicine
Division of Hematology
Department of Medicine
Mayo Clinic
Rochester, MN

Tait D. Shanafelt, MD
Tait D. Shanafelt, MD
Associate Professor of Medicine
Division of Hematology
Department of Medicine
Mayo Clinic
Rochester, MN

Sonali Smith, MD
Sonali Smith, MD
Associate Professor of Medicine
Division of Hematology
Department of Medicine
University of Chicago Medical Center
Chicago, IL

Martin S. Tallman, MD
Martin S. Tallman, MD
Chief of Leukemia Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Moshe Talpaz, MD
Moshe Talpaz, MD
Professor, Department of Internal Medicine
Alexander J. Trotman Professor of Leukemia Research
Associate Director of Translational Research
Associate Chief/Director of Hematologic Malignancies
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

Thomas E. Witzig, MD
Thomas E. Witzig, MD
Professor of Medicine
Division of Hematology
Department of Internal Medicine
Mayo Clinic
College of Medicine
Rochester, MN

Anas Younes, MD
Anas Younes, MD
Director, Clinical and Translational Research Program
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas M.D. Anderson Cancer Center
Houston, TX

2nd Annual Symposium on
Personalized Therapies and Best Clinical Practices
for
Hematologic Malignancies

Grand Hyatt Tampa Bay ~ Saturday February 5, 2011

CASE-BASED LEARNING

Click here for the agenda

This past year a tremendous amount of new "practice-changing" data affecting how you treat, manage and care for your hematology patients has been published. For your lymphoma, myeloma and leukemia patients this symposium will help you apply the new first-line and maintenance therapy data as well as the best practices for your refractory and relapsed patients.

Taught by the expert hematology academics who are highly effective and engaging teachers, this Patient Case-Based program is the ONE symposium on hematologic malignancies that you should attend in 2011. It also provides the important highlights and data from the December 2010 ASH Symposium. So if there is only one hematology CME symposium that you should attend in 2011, please join us on February 5, 2011 in Tampa, FL. This is the second year of this very special symposium. It promises to continue to attract a full room of hematologists and allied health care professionals like you who will leave the symposium with the expert knowledge and competence needed to improve outcomes for patients with hematologic malignancies.

Register now for a guaranteed symposium seat, discounted tuition, hotel room rates and airline fares. Like last year, attendance will reach its maximum. Don't miss this opportunity.

   
•
 Overview
•
 Educational Statement of Need
•
 Disclosure
•
 Target Audience
•
 Learning Objectives
•
 CME Credit Information
•
 Agenda
•
 Grand Hyatt Tampa Bay
•
 Registration
•
 Exhibit
•
 Southwest Airlines
   
Agenda Back to Top
February 5, 2011
6:45AM - 7:45AM Breakfast
7:00AM Registration
7:45AM Welcome and Introductions and CME Pre Test Steven Rosen
Session 1: CRITICAL QUESTIONS IN THE TREATMENT OF LYMPHOMAS AND HODGKIN’S DISEASE Chair: Thomas Witzig
8:00AM Case Study: Progress in the treatment of mantle cell lymphoma: applying the results of the most current clinical trials for both newly diagnosed patients and relapsed patients, a longitudinal review André Goy
8:20AM Case Study: Devising the optimal treatment strategies for newly diagnosed and relapsed/refractory diffuse large B-Cell lymphoma (DLBCL) Leo Gordon
8:40AM Case Study: Additional therapies for follicular lymphoma: managing the challenge of multiple first-line treatment options Thomas Witzig
9:00AM Point-CounterPoint: Follicular lymphoma patients who relapse following initial therapy should receive traditional alternative systemic treatment options rather than a stem cell transplant.
  1. Audience votes pre and post debate via ARS
  2. Expert faculty reviews the audience votes and provides their additional perspectives
 Pro: John Leonard
Con: Sonali Smith
9:30AM Roundtable Panel Discussion: Each faculty provides his perspective on the options for the Point-Counterpoint Session #1 Faculty
9:45AM Q & A and Additional Patient Cases Submitted by the Learners Learners and Faculty
10:00AM BREAK  
10:20AM Case Study: New systemic options for the management of Hodgkin’s Disease Anas Younes
10:40AM Case Study: Peripheral T-Cell Lymphoma: Therapeutic Advances and toxicity issues in optimal therapy selection across all lines of therapy Owen O’Connor
11:00AM Case Study: State-of-the Art Therapies for Primary Cutaneous T-Cell Lymphoma: Building the new treatment algorithm? Steven Rosen
11:20AM Case Study: Personalizing therapies for patients with chronic lymphocytic leukemia (CLL): What are the optimal clinical applications of chemotherapies and targeted therapies in the first-line setting? Shuo Ma
11:40AM Case Study: Relapsed or refractory CLL: what are the optimal systemic therapies for these patients? Tate Shanafelt
12:00PM Q & A and Additional Patient Cases Submitted by the Learners Learners and Faculty
12:30AM LUNCH WITH THE EXPERTS  
Session 2: CRITICAL QUESTIONS IN THE TREATMENT OF MULTIPLE MYELOMA - Session Chair: Vincent Rajkumar
1:30PM Case Study: The optimal treatment of the non-transplant candidates with multiple myeloma: what are the emerging options and optimal strategies? Vincent Rajkumar
1:50PM Case Study: What are the optimal treatment strategies for transplant-eligible candidates with multiple myeloma? Nikhil Munshi
2:10PM Q & A and Additional Patient Cases Submitted by the Learners Learners and Faculty
2:30PM BREAK  
Session 3: CRITICAL QUESTIONS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA AND MYELODYSLASTIC SYNDROMES - Session Chair: Michael Deininger
2:50PM Case Study: New treatment algorithms for initial and relapse therapies of chronic myelogenous leukemia (CML). What are the optimal therapeutic options? Moshe Talpaz
3:10PM Case Study: Best clinical practices for treating acute myeloid leukemia (AML): How do we integrate prognostic factors into optimal treatment decision-making? Michael Deininger
3:30PM Case Study: Management of a newly diagnosed patient with Acute Promyelocytic Leukemia (APL) Martin Tallman
3:50PM Case Study: Myelodysplastic Syndromes - Update 2011 Virginia Klimek
4:10PM Case Study: Treatment of Acute Lymphoblastic Leukemia (ALL) Tibor Kovacsovics
4:30PM Roundtable Panel Discussion: Each faculty provides his or her perspective on the cases Learners and Faculty
4:45PM Final Q & A Learners and Faculty
5:00PM Concluding Remarks and Post-Activity CME questions. Steven Rosen
Educational Grants

Sincere appreciation is extended to the following companies for their generous commercial support of this educational meeting:
© 2012 Biomedical Learning Institute
1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Registration Phone: 214.269.2014 • Fax: 214.866.0311
Contact Us
Disclaimer: The material published on the Biomedical Learning Institute(BLI) Web site reflects the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the BLI, the CME provider, or the commercial supporters providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified physician should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any BLI materials. Click here for our Privacy Policy.